(2019) found that compared to ALF patients, in patients with acute chronic liver failure (ACLF), liver endothelial cells display a significant loss of CXC chemokine receptor type 7 DNA binding inhibitor 1 (CXCR7-ID1) dependent HGF expression, which correlates with the poor hepatocyte proliferation
Product Attributes CAS # : 2103905-91-3 Molecular Formula : C201H325N65O67 Sequence (AA) : (D-Arg)9-LTLRKEPASEIAQSILEAYSQNGWANRRSAGGKRPPPRRRQRRKKRG Molecular Weight : ~4598 g/mol PubChem CID : N/A (peptide not indexed) Half-Life : ~2-4 hours Synonyms : Proxofim, FOXO4-D-Retro-Inverso, FOXO4-p53 Interfering Peptide Type : Synthetic D-retro-inverso peptide (senolytic research compound) Research Focus : Longevity & Senescence, Cellular Repair Scientific References Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging Animal | In vitro FOXO4-DRI peptide selectively induces apoptosis in senescent cells Animal | In vitro Senolytics: Eliminating Senescent Cells and Alleviating Intervertebral Disc Degeneration Animal | In vitro Cellular senescence: Defining a path forward Observational | Animal | In vitro The role of senescent cells in ageing Animal | In vitro FOXO4 peptide disrupts FOXO4-p53 interaction to target senescent cells Animal | In vitro Senolytic therapy alleviates age-associated bone loss in mice Animal | In vitro Therapeutic interventions for aging: the case of cellular senescence Observational | Animal | In vitro Included In The Box Every product arrives in a premium, custom-designed PEPTIDE.Power box , engineered for convenience, hygiene, and safe storage in your refrigerator
Clinical studies demonstrate its ability to improve skin density, firmness, and overall appearance, making it one of the most effective peptides for skin rejuvenation
Do I Need a Prescription for Semorelin/Ipamorelin-CJC1295 or Other Growth Hormone Stimulating Peptide Therapy Injectables
It is important to note that most of these effects have been observed in animal studies, and human clinical trials are currently very limited
Side Effect Profile: advantage goes to PE-22-28
